Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Celltrion’s Stelara Biosimilar to Hit Shelves on July 8
Celltrion Healthcare Japan will launch its biosimilar of the anti-IL-12/23p40 antibody Stelara (ustekinumab) on July 8, making it the third follow-on version of the autoimmune disease treatment available in Japan. The product, Ustekinumab BS SC Injection 45 mg Syringe “CT”,…
To read the full story
Related Article
BUSINESS
- Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
- Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
March 2, 2026
- Shionogi, Torii File Lotion Form of Corectim in Japan
March 2, 2026
- Arcalis Completes mRNA Drug Facility, Establishes End-to-End CDMO Platform
March 2, 2026
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…